JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Jazz Pharmaceuticals plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$208.43−1.80 (-0.86%)
Close on Oct 19, 2026
- Market cap
- $14.47B
- P/E (TTM)
- 14.3
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
-10.1%−26.1 pts over 5 years
Net margin
-8.3%−18.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +4.9% | +5.3% | +12.5% | +12.4% | |
| Free cash flow | -4.5% | +1.4% | +8.0% | +10.1% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 22.1% | 7.0% | -8.5% | |
| Return on assets | 9.8% | 4.0% | -3.0% | |
| Current ratio | 2.91 | 4.34 | 1.86 | |
| Debt to equity | 1.08 | 0.57 | 1.24 | |
| Net debt to EBITDA | 2.76× | 2.61× | -10.21× | |
| Interest coverage | 21.5× | 4.3× | – | |
| Capex to revenue | 0.7% | 0.6% | 1.4% | |
| Diluted shares | 62M | 57M | 61M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Jazz Pharmaceuticals generated $5.89B from operations and spent $883.74M on capital expenditure, dividends and share buybacks. 20% of that went back into the business.
Generated
$5.89B
Used
$883.74M
Capital expenditure$177.47M20%Dividends$00%Share buybacks$706.27M80%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-8.3%
×Asset turnover0.36×
×Equity multiplier2.81×
=Return on equity, FY2025-8.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -8.3% | 0.36× | 2.81× | -8.5% |
| FY2024 | 13.8% | 0.35× | 2.99× | 14.3% |
| FY2023 | 10.8% | 0.34× | 3.26× | 12.2% |
| FY2022 | -6.1% | 0.32× | 3.28× | -6.4% |
| FY2021 | -10.7% | 0.33× | 2.47× | -8.6% |
| FY2020 | 10.1% | 0.39× | 1.78× | 7.0% |
| FY2019 | 24.2% | 0.40× | 1.83× | 17.8% |
| FY2018 | 23.6% | 0.37× | 1.89× | 16.3% |
| FY2017 | 30.1% | 0.33× | 2.16× | 21.3% |
| FY2016 | 26.7% | 0.37× | 2.27× | 22.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$356.15M
- Cash generatingOperating cash flow above zero$1.36B
- Return on assets improvedROA up on the prior year4.9% → -3.0%
- Earnings backed by cashOperating cash flow above net income$1.36B vs -$356.15M
- Less leverageLong-term debt to assets fell50.6% → 37.1%
- Better liquidityCurrent ratio rose4.46 → 1.86
- No dilutionShare count did not rise66M → 61M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.36 → 0.36